<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04249778</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00111588</org_study_id>
    <nct_id>NCT04249778</nct_id>
  </id_info>
  <brief_title>Dapagliflozin Heart Failure Readmission</brief_title>
  <official_title>Dapagliflozin Heart Failure Readmission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be the first trial to evaluate the safety and efficacy of dapagliflozin
      treatment in preventing readmissions/ER visits/urgent clinic visits, and death in patients
      with and without T2D after admission for heart failure. Treatment with SGLT2-i has been shown
      to reduce both heart failure hospitalizations and mortality in patients with established
      heart disease. However, the time of initiation of SGLT2-i therapy has not been evaluated in
      patients with HF. In addition, the impact of treatment on HF symptoms quality of life,
      resource utilization, and cost-effectiveness of dapagliflozin versus placebo will be
      evaluated. The results of this study have great potential to impact and facilitate care and
      to change current clinical guidelines in the management of patients with heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of both heart failure and type 2 diabetes (T2D) or prediabetes are reaching
      epidemic proportions globally and in the United States. More than 40% of patients with
      established heart failure (HF) have diabetes.

      This study will be the first trial to evaluate the safety and efficacy of dapagliflozin
      treatment in preventing readmissions/ER visits/urgent clinic visits, and death in patients
      with and without T2D after admission for heart failure. Treatment with SGLT2-i has been shown
      to reduce both heart failure hospitalizations and mortality in patients with established
      heart disease. However, the time of initiation of SGLT2-i therapy has not been evaluated in
      patients with HF. In addition, the impact of treatment on HF symptoms quality of life,
      resource utilization, and cost-effectiveness of dapagliflozin versus placebo will be
      evaluated. The results of this study have great potential to impact and facilitate care and
      to change current clinical guidelines in the management of patients with heart failure.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite number of hospital admissions, emergency department visits, urgent clinic visits for Heart Failure (HF) and death after admission with acute decompensated heart failure (ADHF)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Composite number of hospital admissions, emergency department visits, urgent clinic visits for Heart Failure (HF) and death after admission with acute decompensated heart failure (ADHF) will be calculated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score</measure>
    <time_frame>Baseline, 6, 12, and 26 weeks</time_frame>
    <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Chronic Heart Failure Questionnaire (CHQ-SAS) score</measure>
    <time_frame>Baseline, 6, 12, and 26 weeks</time_frame>
    <description>The Chronic Heart Failure Questionnaire (CHQ-SAS) assesses patients' perception of their HF and measures the impact of HF symptoms. The CHQ-SAS contains16 standardized questions that assess dyspnea during daily activities, fatigue and emotional function. Items are rated on a 7-point Likert scale ranging from 1 to 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NT-proBNP levels</measure>
    <time_frame>Baseline, 6, 12, and 26 weeks</time_frame>
    <description>Lower HF disease-specific biomarker N-terminal (NT)-pro hormone BNP (NT-proBNP) is a non-active prohormone. Levels goes up when heart failure develops or gets worse, and levels goes down when heart failure is stable. NT-proBNP levels will be quantified by blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute walk distance (6MWD)</measure>
    <time_frame>Baseline, 6, 12, and 26 weeks</time_frame>
    <description>This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline, 6, 12, and 26 weeks</time_frame>
    <description>Change in HbA1c will be quantified by blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>Baseline, 6, 12, and 26 weeks</time_frame>
    <description>Change in weight will be calculated in pounds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>Baseline, 6, 12, and 26 weeks</time_frame>
    <description>Change in systolic blood pressure will be calculated in millimeters of mercury (mmHg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in measures of left ventricular systolic and diastolic function</measure>
    <time_frame>Baseline, 6, 12, and 26 weeks</time_frame>
    <description>Change in measures of left ventricular systolic and diastolic function will be assessed by echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum magnesium</measure>
    <time_frame>Baseline, 6, 12, and 26 weeks</time_frame>
    <description>Serum magnesium will be quantified by blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cardiovascular death cases</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of cardiovascular death cases will be documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of non-fatal myocardial infarction (MI) cases</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of non-fatal myocardial infarction (MI) cases will be documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of stroke cases</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of stroke cases will be documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of acute kidney injury cases</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of acute kidney injury cases will be documented</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">392</enrollment>
  <condition>Heart Failure</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive dapagliflozin 10 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Participants will receive dapagliflozin 10 mg once daily</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>FARXIGA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo tablet once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females between the ages of 18 and 80 years, with or without diabetes,
             ejection fraction of 40% or less, and New York Heart Association (NYHA) class II, III,
             or IV symptoms discharged after hospital admission with a clinical diagnosis ADHF.

          2. Elevated NT-pro-BNP &gt;300 pg/ml or BNP (&gt;100 pg/ml) on admission.

          3. Interpretable echocardiogram during hospital admission.

          4. Blood glucose level &lt;400 mg/dL without evidence of diabetic ketoacidosis (serum
             bicarbonate &lt;18 mEq/L or positive serum or urinary ketones)- Applies to patients with
             T2D.

          5. BMI &gt; 25 Kg/m2 and â‰¤ 45 Kg/m2

        Exclusion Criteria:

          1. Age &lt; 18 or &gt; 80 years.

          2. Subjects with a history of type 1 diabetes.

          3. Treatment with TZDs, GLP1-RA or SGLT2-i during the past 3 months of admission.

          4. Recurrent episodes of severe hypoglycemia or hypoglycemic unawareness.

          5. Patients with a history of recurrent HF admissions considered to be due to
             non-compliance (poor adherence) to medical therapy.

          6. Patients with clinically significant hepatic disease (cirrhosis, jaundice, end-stage
             liver disease, portal hypertension) and elevated ALT and AST &gt; 3 times upper limit of
             normal.

          7. Patients with impaired renal function (GFR &lt; 45 ml/min).

          8. Treatment with oral or injectable corticosteroids (equivalent or higher than
             prednisone 5 mg/day) or immunosuppressive treatment.

          9. Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study.

         10. Patients on ventricular assist devices (VADs)

         11. History of heart transplant or listed for heart transplant

         12. History of cardiac surgery or planned cardiac interventions within the following 6
             months

         13. HF due to restrictive/infiltrative cardiomyopathy, active myocarditis, constrictive
             pericarditis, severe stenotic or regurgitant valvular diseases, hypertrophic
             cardiomyopathy, or congenital heart disease.

         14. History of SGLT2-i allergy

         15. Systolic blood pressure &lt; 100 mmHg

         16. Uncontrolled hypertension, defined as a systolic blood pressure &gt; 200 mmHg at
             randomization

         17. Female subjects who are pregnant or breast feeding at time of enrollment into the
             study.

         18. Females of childbearing potential who are not using adequate contraceptive methods (as
             required by local law or practice).

         19. In hospice or expected life expectancy less than 6 months

         20. Patients with diabetic foot infection, osteomyelitis and history of amputation of
             lower extremities within 6 months of admission

         21. Patients anticipated to undergo major surgical procedures during the following 6
             months

         22. Patients with active hematuria, urinary tract infection (UTI), or history of frequent
             UTIs or genital mycotic infections

         23. Atrial fibrillation or atrial flutter with a resting heart rate &gt;110bpm documented by
             ECG at randomization.

         24. Any condition that in the opinion of the investigator would contraindicate the
             assessment of 6MWD

         25. Chronic pulmonary disease i.e. with known FEV1 &lt;50% requiring home oxygen, or oral
             steroid therapy or hospitalization for COPD exacerbation within 6 months, or
             significant chronic pulmonary disease in the Investigator's opinion, or primary
             pulmonary arterial hypertension

         26. Patients with active or previous history of bladder cancer.

         27. Patients with previous history of diabetic ketoacidosis, per ADA criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <phone>404-778-1665</phone>
    <email>geumpie@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hospitalization</keyword>
  <keyword>mortality</keyword>
  <keyword>time of initiation of therapy</keyword>
  <keyword>quality of life</keyword>
  <keyword>cost-effectiveness</keyword>
  <keyword>dapagliflozin</keyword>
  <keyword>clinical trial</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie results reported, will be shared after de-identification (text, tables, figures, and appendices)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Start 6 months after publication End 5 years after publication</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal. Proposals should be directed to geumpie@emory.edu. To gain access, data requestors will need to sign a data access agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

